Biopharma outsourcing growth has helped to boost the bottom line of Lonza, the world’s largest manufacturer of drug ingredients, though a topsy-turvy Swiss franc has caused the company to hold off on making any projections for 2015.
Shareholders at Swiss pharmaceutical company Roche welcomed the
start of a new era as the company summarised recent events,
including the divestment of the vitamins business, at its annual
general meeting yesterday.